R Squared’s Ginkgo Bioworks DNA Stock Holding History

R Squared’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-870	Closed	-$8.54K	–	619
2024 Q4	$8.54K	Buy	+870	New	+$7.46K	0.01%	1190

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

R Squared's DNA Position: Q1 2025 in Review

R Squared sold out of Ginkgo Bioworks (DNA) in Q1 2025, closing a stake of 870 shares — an estimated $8.54K sold.

R Squared first reported a position in DNA in Q4 2024 and held it in 1 quarter. The position peaked at $8.54K in Q4 2024. 167 funds tracked by Wall St. Rank hold DNA as of Q1 2025.

R Squared reported no remaining Ginkgo Bioworks position as of Q1 2025 after selling out during the quarter.
R Squared sold 870 Ginkgo Bioworks shares in Q1 2025, an estimated $8.54K.
R Squared first reported a position in Ginkgo Bioworks in Q4 2024 and held it in 1 quarter.
R Squared's Ginkgo Bioworks position peaked at $8.54K in Q4 2024.
167 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.